Literature DB >> 33724059

Dihydromyricetin Exhibits Antitumor Activity in Nasopharyngeal Cancer Cell Through Antagonizing Wnt/β-catenin Signaling.

Ling Ye1, Gendi Yin2, Miaohua Jiang1, Bo Tu1, Zhicheng Li2, Yiming Wang1.   

Abstract

BACKGROUND: Cancer stem cells (CSCs) have been demonstrated to play a vital role in a diversity of biological processes in cancers. With the emergence of new evidence, the important function of CSCs in the formation of multidrug resistance of nasopharyngeal cancer has been demonstrated. Dysregulated Wnt/β-catenin signaling pathway is an important contributor to chemoresistance and maintenance of CSCs-like characteristics. This research aims to investigate comprehensively the function of dihydromyricetin (DMY), a natural flavonoid drug, on the cisplatin (cis) resistance and stem cell properties of nasopharyngeal cancer.
METHODS: In this study, the functional role of DMY in nasopharyngeal cancer progression was comprehensively investigated in vitro and in vivo, and then its relationship with CSCs-like phenotypes and multiple oncogenes was analyzed.
RESULTS: In parallel assays, the growth inhibitory action of cis was enhanced by the addition of DMY in cis-resistant nasopharyngeal cancer cell lines (Hone1/cis and CNE1/cis). Functional assays showed that DMY markedly diminished the stem cell properties of nasopharyngeal cells, such as colony and tumor-sphere formation. In vivo data showed that the growth of Hone1 CSCs formed tumor xenograft was inhibited significantly by the administration of DMY. Additionally, DMY could impair the Wnt/β-catenin signaling pathway and regulate the expression of downstream proteins in nasopharyngeal cancer cells.
CONCLUSIONS: Our study clarified the anti-tumor activity of DMY through blocking the Wnt/β-catenin signaling pathway in nasopharyngeal cancer. Therefore, DMY could be a novel therapeutic agent for nasopharyngeal cancer treatment.

Entities:  

Keywords:  Wnt/β-catenin signaling; cancer stem cell; dihydromyricetin; nasopharyngeal cancer

Year:  2021        PMID: 33724059      PMCID: PMC7975991          DOI: 10.1177/1534735421991217

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  39 in total

Review 1.  Wnt/β-catenin signaling and disease.

Authors:  Hans Clevers; Roel Nusse
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

2.  Long noncoding RNA SNHG16 contributes to the development of bladder cancer via regulating miR-98/STAT3/Wnt/β-catenin pathway axis.

Authors:  Feng Feng; Aiping Chen; Junjian Huang; Qinghua Xia; Yougen Chen; Xunbo Jin
Journal:  J Cell Biochem       Date:  2018-08-21       Impact factor: 4.429

3.  Sulforaphane promotes apoptosis, and inhibits proliferation and self-renewal of nasopharyngeal cancer cells by targeting STAT signal through miRNA-124-3p.

Authors:  Xiqing Li; Zunlan Zhao; Ming Li; Mingyue Liu; Andres Bahena; Yaping Zhang; Yuwei Zhang; Chetan Nambiar; Guangzhi Liu
Journal:  Biomed Pharmacother       Date:  2018-04-24       Impact factor: 6.529

4.  Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.

Authors:  Anne G Christensen; Sidse Ehmsen; Mikkel G Terp; Richa Batra; Nicolas Alcaraz; Jan Baumbach; Julie B Noer; José Moreira; Rikke Leth-Larsen; Martin R Larsen; Henrik J Ditzel
Journal:  Stem Cells       Date:  2017-06-23       Impact factor: 6.277

Review 5.  Factors affecting the nuclear localization of β-catenin in normal and malignant tissue.

Authors:  Rhys G Morgan; Jenna Ridsdale; Alex Tonks; Richard L Darley
Journal:  J Cell Biochem       Date:  2014-08       Impact factor: 4.429

6.  Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway.

Authors:  Tiffany J Rios-Fuller; Gabriela Ortiz-Soto; Mercedes Lacourt-Ventura; Gerónimo Maldonado-Martinez; Luis A Cubano; Robert J Schneider; Michelle M Martinez-Montemayor
Journal:  Oncotarget       Date:  2018-11-13

7.  Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.

Authors:  Karolina Sterzyńska; Andrzej Klejewski; Karolina Wojtowicz; Monika Świerczewska; Marta Nowacka; Dominika Kaźmierczak; Małgorzata Andrzejewska; Damian Rusek; Maciej Brązert; Jacek Brązert; Michał Nowicki; Radosław Januchowski
Journal:  Int J Mol Sci       Date:  2018-12-23       Impact factor: 5.923

8.  The Disruption of the β-Catenin/TCF-1/STAT3 Signaling Axis by 4-Acetylantroquinonol B Inhibits the Tumorigenesis and Cancer Stem-Cell-Like Properties of Glioblastoma Cells, In Vitro and In Vivo.

Authors:  Heng-Wei Liu; Yu-Kai Su; Oluwaseun Adebayo Bamodu; Dueng-Yuan Hueng; Wei-Hwa Lee; Chun-Chih Huang; Li Deng; Michael Hsiao; Ming-Hsien Chien; Chi-Tai Yeh; Chien-Min Lin
Journal:  Cancers (Basel)       Date:  2018-12-05       Impact factor: 6.639

9.  Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6.

Authors:  Geng Wu; He Huang; Jose Garcia Abreu; Xi He
Journal:  PLoS One       Date:  2009-03-18       Impact factor: 3.240

10.  CSCs: regenerating optimism for osteosarcoma treatment.

Authors:  Adam S Levin
Journal:  Oncotarget       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.